New Delhi: Dr Reddy’s Laboratories and UCB, a biopharmaceutical company announced they have entered into a distribution and co-promotion agreement for Briviact (Brivaracetam) for India.
According to a press release issued by Dr Reddys, the agreement grants it the exclusive right to distribute Briviact in India.
The drug is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older.
UCB Neurology Patient Value Unit, head of International Markets, Max Bricchi said, “This partnership is another important step towards us providing value together to patients by making Briviact available as an additional treatment choice for epilepsy.”
Epilepsy is the second most common neurological condition and as per a recent study, an estimated 70 million people suffer from it worldwide while there are over 12 million people suffering from epilepsy in India, which contributes to nearly one-sixth of the global burden, the release said.
Latest posts by Ruby Khatun (see all)
- JnJ faulty hip implants case: CIC directs RTI disclosure of records - September 10, 2018
- Max Bupa launches WeCare initiative to aid Kerala flood victims - September 10, 2018
- Opposing Online Pharmacies, 8.5 lakh chemists to call it a strike on September 28 - September 9, 2018